[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 52, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sean P. Nolan", "age": 55, "title": "CEO & Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 925331, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sukumar  Nagendran M.D.", "age": 56, "title": "President, Head of Research & Development and Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 820594, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamran  Alam CPA, M.B.A.", "age": 45, "title": "CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 573362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hayleigh  Collins", "title": "Director of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy M. Porter SPHR", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick  Porter Ph.D.", "title": "Chief of Staff & Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  McGinnis M.P.H.", "title": "Chief Patient Advocacy & External Affairs Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  McAuliffe", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven  Gray Ph.D.", "title": "Chief Scientific Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Berge  Minassian M.D.", "title": "Chief Medical Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.57, "open": 2.54, "dayLow": 2.495, "dayHigh": 2.62, "regularMarketPreviousClose": 2.57, "regularMarketOpen": 2.54, "regularMarketDayLow": 2.495, "regularMarketDayHigh": 2.62, "beta": 0.262, "forwardPE": -5.458333, "volume": 858089, "regularMarketVolume": 858089, "averageVolume": 2901365, "averageVolume10days": 1323000, "averageDailyVolume10Day": 1323000, "bid": 2.6, "ask": 2.66, "bidSize": 600, "askSize": 100, "marketCap": 489987136, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 3.89, "priceToSalesTrailing12Months": 31.712326, "fiftyDayAverage": 2.6475, "twoHundredDayAverage": 2.13832, "currency": "USD", "enterpriseValue": 407932896, "floatShares": 100105272, "sharesOutstanding": 187018000, "sharesShort": 16067454, "sharesShortPriorMonth": 15811726, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0859, "heldPercentInsiders": 0.18466, "heldPercentInstitutions": 0.70655996, "shortRatio": 4.17, "shortPercentOfFloat": 0.117, "impliedSharesOutstanding": 187018000, "bookValue": 0.401, "priceToBook": 6.5336657, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -111566000, "trailingEps": -0.96, "forwardEps": -0.48, "enterpriseToRevenue": 26.402, "enterpriseToEbitda": -5.827, "52WeekChange": 2.6299436, "SandP52WeekChange": 0.24486005, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TSHA", "underlyingSymbol": "TSHA", "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "firstTradeDateEpochUtc": 1600954200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fa02d192-bc05-33bd-8c2b-2973d0bcc5d6", "messageBoardId": "finmb_665948579", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.62, "targetHighPrice": 9.0, "targetLowPrice": 2.0, "targetMeanPrice": 6.35, "targetMedianPrice": 7.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 143940000, "totalCashPerShare": 0.77, "ebitda": -70003000, "totalDebt": 61885000, "quickRatio": 3.916, "currentRatio": 4.077, "totalRevenue": 15451000, "debtToEquity": 82.583, "revenuePerShare": 0.133, "returnOnAssets": -0.29838, "returnOnEquity": -2.94036, "freeCashflow": -68508496, "operatingCashflow": -73018000, "revenueGrowth": 0.44, "grossMargins": 1.0, "operatingMargins": -4.38319, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-07"}]